Raymond R. Townsend, MD; 1 Alan D. Forker, MD, MACP; 2 Vaishali Bhosekar, MSc; 3 Anthony Yadao, MD; 4 Deborah L. Keefe, MD, MPh 4

ORIGINAL PAPER Comparison of Aliskiren ⁄Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hyperte...

Author: Mavis Porter

5 downloads 3 Views 218KB Size

Report

Download PDF

Recommend Documents

Standard Time Telling Time Activities National Standards: (1.MD.3.) (2.MD.7.) (3.MD.1.) (4.MD.1.) (4.MD.2.) (5.MD.1.)

Francini Placencia MD, MPH, MSC

Noppakorn Prakansamut MD*, Porntip Sirayapiwat MD, MSc*, Surang Triratanachat MD*

November 01, 2015 Cancer Management [1] By Judd W. Moul, MD [2], Tian Zhang, MD [3], Andrew J. Armstrong, MD, MSc [4], and Joseph Lattanzi, MD [5]

DISTAL BICEPS TENDON RUPTURES David D Savin MD, Simon Lee MPH, Jonathan N Watson MD, Ari R Youderian MD, Mark R Hutchinson MD, Benjamin Goldberg MD

Martin Petzoldt MD, Stephan Braune MD MPH, Iris Bittmann MD, and Stefan Kluge MD

MD-4 INSTRUCTION MANUAL

Charles V. Pollack, Jr., MA, MD Matthew T. Roe, MD, MHS Eric D. Peterson, MD, MPH

DEBORAH A. FARYNIARZ, MD

ORIGINAL ARTICLE. Kenneth W. Altman, MD, PhD; Gou-Pei Yu, MD, MPH; Steven D. Schaefer, MD

Marci Goolsby, MD Joshua Hackel, MD Mederic M. Hall, MD Eugene Hong, MD Neeru Jayanthi, MD Kelsey Logan, MD, MPH Dawn Mattern, MD

BROWN TUMORS AND THE ATYPICAL PARATHYROID ADENOMA Junao Wang MD 1, Paari Murugan MD 2, Khalid Amin MD 2, Elizabeth Seaquist MD 3, Lisa Chow MD,MS 3

Robert C Welsh MD FRCPC 1, Andrew Travers MD 2, Thao Huynh MD 3, Warren J Cantor MD 4,5

Florian Brunner, MD 1, Adrian Gymesi, MD 2, Rudolf Kissling, MD 1, and Lucas M. Bachmann, MD, PhD 2

MD-3

4. BENIGN PROSTATIC HYPERPLASIA (BPH) Steven Asch MD, MPH, and John Roland Franklin, MD

Linda B. Piller, MD, MPH

Julia B. Greer, MD MPH

OTOSCLEROSIS. Timothy C. Hain, MD and Alan Micco, MD

BRUCE C. PERRY, MD MPH

REVIEW REVUE. Daniel Waltho, MD Gloria Rockwell, MD, MSc

Gregory D. Schroeder, MD, Christopher K. Kepler, MD, MBA, and Alexander R. Vaccaro, MD, PhD

Anastasios Papadonikolakis, MD, Mark McKenna, MD, Winston Warme, MD, Brook I. Martin, PhD, MPH, and Frederick A. Matsen III, MD

ORIGINAL

PAPER

Comparison of Aliskiren ⁄Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus Raymond R. Townsend, MD;1 Alan D. Forker, MD, MACP;2 Vaishali Bhosekar, MSc;3 Anthony Yadao, MD;4 Deborah L. Keefe, MD, MPh4 From the University of Pennsylvania Medical Center, Philadelphia, PA;1 St Luke’s Lipid and Diabetes Research Center, Kansas City, MO;2 Novartis Healthcare Pvt Ltd, Madhapur, Hyderabad, India;3 and Novartis Pharmaceuticals Corporation, East Hanover, NJ4

Patients with stage 2 hypertension and diabetes are at high cardiovascular risk and require large blood pressure (BP) reductions to reach treatment goals. This randomized double-blind study compared aliskiren ⁄ hydrochlorothiazide (HCTZ) combination therapy with amlodipine monotherapy in 860 patients with mean sitting systolic BP (msSBP) 160 mm Hg to